Ruxolitinib

In this article, we will discuss about Ruxolitinib (Dosage Overview). So, let’s get started.

Ruxolitinib is a kinase inhibitor indicated for treatment of patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis.

Dosage

• The starting dose of ruxolitinib is 20 mg given orally twice daily for patients with a platelet count greater than 200 X 109/L, and 15 mg twice daily for patients with a platelet count between 100 X 109/L and 200 X 109/L.
• Perform a complete blood count before initiating therapy with Jakafi. Monitor complete blood counts every 2 to 4 weeks until doses are stabilized, and then as clinically indicated. Modify dose for thrombocytopenia.
• Increase dose based on response and as recommended to a maximum of 25 mg twice daily. Discontinue after 6 months if no spleen reduction or symptom improvement.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.